CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics
Beside cardiovascular diseases, malignant tumours take
the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Innovative protocol maps NMDA receptors in Alzheimer’s-Affected brains
Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of…
New insights into sleep
…uncover key mechanisms related to cognitive function. Discovery suggests broad implications for giving brain a boost. While it’s well known that sleep enhances cognitive performance, the underlying neural mechanisms, particularly…
3D-printing advance
… mitigates three defects simultaneously for failure-free metal parts. University of Wisconsin–Madison engineers have found a way to simultaneously mitigate three types of defects in parts produced using a prominent…